Last reviewed · How we verify
A Phase II Study of Pazopanib in Combination With Capecitabine and Oxaliplatin (CAPEOX) in Patients With Advanced Gastric Cancer
In order to improve survival of metastatic gastric cancer patients, we plan to to conduct a phase II trial of CapeOx with 800 mg once-daily pazopanib as a first-line chemotherapy in metastatic gastric cancer patients.
Details
| Lead sponsor | Samsung Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 66 |
| Start date | 2010-12 |
| Completion | 2015-12 |
Conditions
- Gastric Cancer
Interventions
- Pazopanib in combination with capecitabine and oxaliplatin
Primary outcomes
- Response rate — 6 months after last patient
Countries
South Korea